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We describe the clinical features of a man with Muir– Torre syndrome (MTS) who was 
recently diagnosed with gastric adenocarcinoma and then presented to the Mohs 
micrographic surgery (MMS) unit for treatment of chin and neck lesions. Final pathology 
confirmed that both lesions were gastric adenocarcinoma cutaneous metastases; we 
report the first case of cutaneous metastasis from gastric adenocarcinoma in a patient 
with MTS. Cutaneous metastases are rare and account for just 2% of all skin cancers. 
They generally manifest as dermal nodules, although morphology may vary. Cutaneous 
metastases are often found overlying the visceral malignancy, but they may also appear 
at distant locations. The most common cancers associated with cutaneous metastases 
include breast, colon, lung, and melanoma.1 A 46-year-old Caucasian man with MTS 
presented to the MMS unit for treatment of an erythematous nodule on the chin and an 
erythematous nodule on the posterior neck. He had a left pubic sebaceous carcinoma 
excised 2 years ago and a strong family history of malignancy. Three months before 
MMS, the patient had been diagnosed with metastatic gastric adenocarcinoma by 
gastroenterology. After his first cycle of chemotherapy, the patient alerted his oncologist 
about a tender cystic nodule on the chin that had been present for several months. The 
oncologist performed fine needle aspiration. Cytopathologic examination was consistent 
with malignant epithelial cells (Figure 1); the differential diagnosis included sebaceous 
carcinoma and gastric adenocarcinoma cutaneous metastasis. A referral to dermatology 
was subsequently made. Cutaneous examination of the chin revealed a 1.5-cm 
erythematous nodule (Figure 2A). In addition, a 1-cm nontender erythematous nodule 
was noted on the left posterior neck (Figure 2B); the patient stated that the latter lesion 
had been present for many weeks. The clinical differential diagnosis included cutaneous 
metastasis, epidermal inclusion cyst, and sebaceous carcinoma. The patient was referred 
to the MMS unit for surgical treatment. Excisional biopsy was performed on the neck 
nodule, whereas MMS was conducted on the chin nodule. The tumor-positive margins on 
the first MMS layer showed a poorly differentiated carcinoma consisting of basaloid cells 
(Figure 3). The tumor was completely cleared after 2 additional MMS layers. 
Reconstruction was then performed with a complex linear closure. Debulked and 
nonmarginal MMS tissue blocks from the chin and the excised lesion from the neck were 
sent for permanent pathology (formalin-fixed and paraffin embedded) to clarify the final 
diagnosis. On permanent sections, both specimens appeared identical: poorly 
differentiated malignant neoplasm with glandular structures, signet ring cell appearance, 
and “dirty” necrosis with highly pleomorphic cells were seen (Figure 4). Malignant cells 
were weakly positive for CK7 and weakly and focally positive for CDX-2. P63, androgen 
receptor, CK20, and D2-40 stains were negative. Based on this morphology and 
immunohistochemical profile, the carcinoma appeared consistent with metastasis from 
the patient’s known gastric adenocarcinoma. The patient returned to the MMS unit for 2-
week postoperative follow-up. Both scars were found to be healing well, and he was 
referred back to oncology. After 7 cycles of chemotherapy, the patient was transitioned 




Figure 1. Low (A, x200) and high (B, x600) power views of the fine needle aspiration 
biopsy from the chin nodule (direct smear with Diff-Quick stain) show numerous loosely 
cohesive groups of atypical, frankly malignant epithelial cells. 
 
Figure 2. (A) Solitary erythematous nodule is seen on the chin (A), whereas a small 
erythematous nodule is evident on the left posterior neck (B). 
 
Figure 3. The first Mohs micrographic surgery layer supports cutaneous metastasis by 
showing infiltrative strands of poorly differentiated carcinoma cells disconnected from the 
epidermis (A: frozen section, H&E original magnification x20). Higher magnification 
reveals poorly differentiated neoplasm with nuclear polymorphism (B: frozen section, H&E 




Figure 4. Formalin-fixed, paraffin-embedded section from the chin nodule confirms 
cutaneous metastasis by displaying a poorly differentiated malignant carcinoma with 
glandular structures lacking epidermal connection (A: H&E original magnification x40). 
Higher magnification displays dirty necrosis (blue arrow) and signet ring cells (black 
arrows) (B: H&E original magnification x400) 
 
DISCUSSION 
 Muir–Torre syndrome is a variant of hereditary nonpolyposis colorectal cancer (HNPCC) 
syndrome, which is also known as Lynch syndrome. Approximately 9% of patients with 
known HNPCC are affected by MTS; this diagnosis should be clinically suspected when 
patients develop at least one sebaceous neoplasm before the age of 60 years in the 
context of personal or family history of Lynch syndrome–related cancers. Sebaceous 
neoplasms seen in MTS include adenoma, carcinoma, and sebaceoma, although MTS 
patients also develop multiple keratoacanthomas. MTS I, which represents 65% of cases, 
is inherited in an autosomal dominant fashion. The diagnosis of MTS I is supported by 
abnormal mismatch repair (MMR) protein staining on immunohistochemistry and 
microsatellite instability by genetic testing. By comparison, the autosomal recessive MTS 
II should be considered in patients in whom no MMR defects are found.2 The most 
common internal malignancy in MTS is colorectal adenocarcinoma. Other reported 
malignancies include cancers of the brain, breast, endometrium, noncolonic 
gastrointestinal tract, lung, ovary, pancreas, and uroepithelial tract.2 Metastatic disease 
is not uncommon in MTS; in an analysis of 52 MTS patients with internal malignancies, 
60% of patients developed metastases to various sites.3 However, to the best of our 
knowledge, there has only been 1 previously reported case of cutaneous metastasis in a 
patient with MTS; the previous case was a 41-year-old woman who developed a facial 
cutaneous metastasis from mucinous hepatic cholangiocarcinoma. Although our patient 
demonstrated loss of expression of mutator L homologue (MLH) 1, the other patient had 
a genetic mutation in mutator S homologue (MSH) 2.4 Cutaneous metastasis has been 
reported to occur in only 0.8% of all gastric cancers and in 3% of colorectal cancers.5 
Cutaneous metastases may arise from local spread to overlying skin, although more 
 
 
distant spread is likely through blood vessels or dermal lymphatics. Prompt recognition of 
cutaneous metastases may decrease morbidity and mortality.5 
Dermatologic surgeons should consider the possibility of cutaneous metastasis in 
patients with MTS. Shave or punch biopsies are the preferred method to confirm 
histological diagnosis and should be sought for definite diagnostic confirmation of 
malignant epithelial cells found by fine-needle aspiration biopsy before referral for MMS. 
However, if malignant lesions involve cosmetically sensitive facial areas, are 
symptomatic, and contribute to the patient’s anxiety, then complete removal of the lesions 
through MMS can be considered. By performing MMS directly, patients avoid a second 
procedure and limit a delay in diagnosis. If MMS is performed in this context, the debulked 
tumor should be sent to pathology to clearly define the malignant lesions. The diagnosis 
of cutaneous metastases should prompt a thorough review of systems, a symptom guided 
initial laboratory work-up, and immediate referral to an oncologist for cancer staging. 
Further referrals of patients with MTS and cutaneous metastases should include 
gastroenterology and dermatology. Gastroenterologists will offer screening 
colonoscopies and upper endoscopies, whereas dermatologists should conduct annual 
full-body skin examinations to monitor for sebaceous carcinomas, keratoacanthomas, 
and cutaneous metastasis.  
CONCLUSION 
We report the first case of cutaneous metastasis from gastric adenocarcinoma in a patient 
with MTS. Our patient arrived at the MMS unit without a definitive diagnosis; thus, the 
preoperative pretest probability for sebaceous carcinoma was high given the known 
propensity of patients with MTS to develop sebaceous neoplasms. Because cutaneous 
metastases may have variable morphology and distant sites of presentation, the 
differential diagnosis for new lesions in patients with MTS should include cutaneous 
metastasis. 
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